REFERENCES
- Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332:411–415.
- Desai D, He S, Yorio T, et al. Hypoxia augments TNF-alpha-mediated endothelin-1 release and cell proliferation in human optic nerve head astrocytes. Biochem Biophys Res Commun. 2004;318:642–648.
- Remuzzi G, Perico N, Benigni A. New therapeutics that antagonize endothelin: Promises and frustrations. Nat Rev Drug Discov. 2002;Dec 1:986–1001.
- Yorio T, Krishnamoorthy R, Prasanna G. Endothelin: Is it a contributor to glaucoma pathophysiology? J Glaucoma. 2002;11:259–270.
- Sugiyama T, Moriya S, Oku H, et al. Association of endothelin-1 with normal tension glaucoma: Clinical and fundamental studies. Surv Ophthalmol. 1995;39(Suppl 1):S49–S56.
- Emre M, Orguel S, Haufschild T, Shaw SG, Flammmer J. Increased plasma endothelin-1 levels in patients with progressive open angle glaucoma. Br J Ophthalmol. 2005;89:60–63.
- Tezel G, Kass MA, Kolker AE, et al. Plasma and aqueous humor endothelin levels in primary open-angle glaucoma. J Glaucoma. 1997;6:83–89.
- Polak K, Petternel V, Luksch A, et al. Effect of endothelin and BQ123 on ocular blood flow parameters in healthy subjects. Invest Ophthalmol Vis Sci. 2001;42:2949–2956.
- Polak K, Luksch A, Frank B, et al. Regulation of human retinal blood flow by endothelin-1. Exp Eye Res. 2003;76:633–640.
- Prasanna G, Krishnamoorthy R, Clark AF, et al. Human optic nerve head astrocytes as a target for endothelin-1. Invest Ophthalmol Vis Sci. 2002;43:2704–2713.
- Taniguchi T, Shimazawa M, Sasaoka M, et al. Endothelin-1 impairs retrograde axonal transport and leads to axonal injury in rat optic nerve. Curr Neurovasc Res. 2006;3:81–88.
- Minckler DS, Bunt AH, Johanson GW. Orthograde and retrograde axoplasmic transport during acute ocular hypertension in the monkey. Invest Ophthalmol Vis Sci. 1977;16:426–441.
- Nyborg N, Prieto D, Benedito S, et al. Endothelin-1-induced contraction of bovine retinal small arteries is reversible and abolished by nitrendypine. Invest Ophthalmol Vis Sci. 1991;32:27–31.
- Takei K, Sato T, Nonoyama T, et al. Analysis of vasocontractile responses to endothelin-1 in rabbit retinal vessels using an ETA receptor antagonist and an ETB receptor agonist. Life Sci. 1993;53:111–115.
- Bursell S, Clermont A, Oren B, et al. The in vivo effect of endothelins on retinal circulation in nondiabetic and diabetic rats. Invest Ophthalmol Vis Sci. 1995;36:596–607.
- Hein TW, Ren Y, Yuan Z, et al. Functional and molecular characterization of the endothelin system in retinal arterioles. Invest Ophthalmol Vis Sci. 2009;50:3329–3336.
- Mulvany MJ, Halpern W. Mechanical properties of vascular smooth muscle cells in situ. Nature. 1976;260:617–619.
- Benjamini Y, Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Stat Soc. 1995;57:289–300.
- Smolander J, Vogt B, Maillard M, et al. Dose-dependent acute and sustained renal effects of the endothelin receptor antagonist avosentan in healthy subjects. Clin Pharmacol Ther. 2009;85:628–634.
- Dieterle W, Mann J, Kutz K. Pharmacokinetics and pharmacodynamics of the ETA-selective endothelin receptor antagonist SPP301 in healthy human subjects. J Clin Pharmacol. 2004;44:59–66.
- Resch H, Karl K, Weigert G, et al. Effect of dual endothelin receptor blockade on ocular blood flow in patients with glaucoma and healthy subjects. Invest Ophthalmol Vis Sci. 2009;50:358–363.
- Riezebos J, Watts IS, Vallance PJ. Endothelin receptors mediating functional responses in human small arteries and veins. Br J Pharmacol. 1994;111:609–615.
- Deng LY, Li JS, Schiffrin EL. Endothelin receptor subtypes in resistance arteries from humans and rats. Cardiovasc Res. 1995;29:532–535.